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Epithelial ovarian cancer (EOC) metastasis to the omentum requires implantation and angiogenesis. We propose
that prometastatic changes in the omental endothelium (for angiogenesis) and mesothelium (for implantation) are
critical. We investigated the expression of angiogenic proteases [cathepsin D (CD), cathepsin L (CL), and matrix
metalloproteinase 2 (MMP2) and MMP9] and vascular endothelial growth factor A (VEGFA) in the mesothelium and
endothelium of omentum from patients with EOC with omental metastases and control patients with benign
ovarian tumors. Endothelial expression of CL, VEGFA, and MMP9 and mesothelial expression of VEGFA, MMP9,
and CD were significantly increased in patients with metastasized EOC. High expression of MMP9 and VEGFA in
endothelium and mesothelium and CD in mesothelium was positively associated with poor disease-specific
survival (DSS). High MMP9 expression in either endothelium or mesothelium and presence of ascites
prospectively showed the greatest risk of shorter DSS [hazard ratio (HR)= 6.16, 95% confidence interval (CI) =
1.76-21.6, P = .0045; HR = 11.42, 95% CI = 2.59-50.35, P = .0013; and HR = 6.35, 95% CI = 2.01-20.1, P = .002,
respectively]. High endothelial MMP9 expression and ascites were independent predictors of reduced DSS and
overall survival, together resulting in worst patient prognosis. Our data show that omental metastasis of EOC is
associated with increased proangiogenic protein expression in the omental endothelium and mesothelium.
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Epithelial ovarian cancer (EOC) is associated with a high mortality
rate due to the late stage of the disease and transperitoneal
spread at the time of presentation [1]. EOC often spreads to the
omentum where the rich vasculature promotes tumor invasion,
angiogenesis, and subsequent metastatic growth. This process
requires complex interactions between cancer cells and the
surrounding omental tissue including the mesothelial, endothelial,
stromal, and myeloid cells and the production of pro-metastatic
and angiogenic stimuli [2–4].
Successful tumor angiogenesis requires the complex temporal and
spatial integration of pro-angiogenic molecules including growth
factors such as vascular endothelial growth factor A (VEGFA),
cytokines, extracellular matrix (ECM) components, adhesion mole-cules, and also proteolytic enzymes [5,6]. These enzymes include the
matrix metalloproteinases (MMPs) and cathepsins that degrade the
ECM, aiding new vessel branching, and it is now clear that they play a
Table 1. Clinicopathologic Characteristics of Patients with Benign Ovarian Tumor and Metastatic
SerousOvarian Carcinoma [on the Basis of CA125 Level, PatientsWereGrouped as Low (b35 IU/ml)
or High (≥35 IU/ml)].
Variable Number
Control Malignant
Median age (range) 61.5 (44-90) 64 (38-83)
Tumor type
Benign 20 –
Malignant – 19
Histologic subtype
Serous 20 19
FIGO stage
3B – 4
3C – 15
Ascites
Absent 20 4
Present (b/N100 ml) – 4/11
Preoperative CA125 (IU/ml)
(1) Low 14 –
(2) High 6 19
Mean 32.8 820.6
Median (range) 19.5 (7-111) 427 (46-2461)
Relapse (based on months)
Present (b/N24 months) 1 (0/1) 17 (5/12)
Absent (N24 months) 19 2
Distant metastasis
No 20 3
Yes – 16
OS
Alive 17 7
Deceased 3 12
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releases pro-angiogenic basic fibroblast growth factor from the ECM
in breast cancer cells, whereas cathepsin L (CL) plays a role in the
angiogenic switching of hyperplastic and dysplastic progenitor lesions
in a mouse model of cervical cancer, as well as in tumor growth and
tumor vascularization [7,8].
Accumulating evidence suggests that proteases play an important
role in EOC. Not only is there a complex interplay between VEGFA
and MMPs during EOC metastasis [9], but also EOC expression of
VEGFA, MMPs, and cathepsins is associated with advanced stage
disease, poor prognosis, and clinicopathologic parameters in patients
with EOC [10–12]. Additionally, high MMP2/9 expression in
primary EOC was significantly associated with aggressive features
such as high stage, high grade, ascites, and positive lymph node status
[13]. Importantly, preoperative serum levels of CL and MMP9
correlated with the degree of differentiation, the International
Federation of Gynecology and Obstetrics (FIGO) staging, and
peritoneal metastasis in patients with EOC [14].
The above work has focused on primary EOC cells. However,
given the unfavorable prognostic outcome associated with omental
metastatic lesions, pro-angiogenic changes in the omentum during
metastasis may also contribute to EOC patient outcome. For
instance, vascular endothelial cells are critical to the angiogenic
process, stimulating ECM remodeling and facilitating new vessel
growth, whereas mesothelial cells may provide metastatic cancer
cells with a microenvironment conducive to survival and growth
[15]. For both cell types, the presence of metastatic EOC cells in
the omentum may change their protease expression profile, shifting
them toward a pro-angiogenic, cancer-inducing response. There-
fore, this study aimed to 1) examine the expression of MMP2,
MMP9, CD, CL, and VEGFA in EOC, endothelial, and
mesothelial cells in the omentum of patients with metastatic
ovarian high-grade serous carcinoma compared with control
patients with benign ovarian cystadenoma and 2) investigate the
relationship between their expression in each cell type and clinical
outcome for patients with EOC. We show that the endothelium
and mesothelium of omentum hosting EOC metastases express
significantly increased levels of pro-angiogenic proteases and
VEGFA and that high endothelial and mesothelial expression of
MMP9 is associated with significantly reduced overall survival (OS)
and disease-specific survival (DSS). Importantly, high endothelial
MMP9 expression combined with the presence of ascites is
predictive of poor prognosis.
Materials and Methods
Clinical Samples
This study was undertaken in the diagnostic/research laboratory of
the Royal Devon and Exeter NHS Foundation Trust (RD&E NHS
Trust). Thirty-nine omental samples taken during ovarian tumor
surgery and previously used for diagnostic staging were retrieved from
the histopathology archives with approval from the Caldicott
Guardian of the RD&E NHS Trust and the Devon and Torbay
Local Research Ethics Committee. Hematoxylin and eosin stained
slides were reviewed by histopathologists (N.C. and M.A.) to confirm
the histopathologic diagnosis and tumor grading. Clinical informa-
tion was obtained from the patients’ medical records. Two distinct
groups were identified: 1) women with high-grade, serous ovarian
carcinoma with omental metastases (malignant group) and 2) womenwith benign ovarian pathology, i.e., serous cystadenoma and normal
omental biopsies (control group).
Immunohistochemistry
Four-micrometer slices of formalin-fixed (10%), paraffin-embedded
tissues were collected onto positively charged microscope slides and
immunostained using primary mouse monoclonal antibodies for
CD, MMP2, MMP9 (Novocastra), CL (Santa Cruz Biotechnol-
ogy, Dallas, TX), and VEGFA (Abcam, Cambridge, UK). Details
of the antibodies used and the preliminary testing to determine
optimum working antibody concentrations and antigen recovery
are presented in Table W1. Representative images of positive
controls are presented in Figure W1. Antigen recovery, depar-
affinization, rehydration, and immunohistochemistry were carried
out by the Bond-MAX autostainer supplied with BOND reagents
(Leica Microsystems, Milton Keynes, UK) at room temperature,
unless otherwise specified. The following immunohistochemical
protocol was applied to each slide with washes with bond wash
buffer between stages 1 and 4 and dH2O for subsequent rinses: 1)
if required, antigen retrieval was performed; 2) primary antibody
(15 minutes); 3) peroxide block (5 minutes); 4) post primary
polymer penetration enhancer (8 minutes) and then 3× wash,
followed by polymer poly-HRP anti-mouse/rabbit IgG containing
10% (vol/vol) animal serum (8 minutes); 5) 3,3′-diaminobenzidine
(DAB, parts 1 and 2) mixed by Bond-MAX (10 minutes) and then
6× wash followed by enhancer (5 minutes) and 3× wash; 6)
counterstain with hematoxylin (0.02% wt/vol; 4 minutes),
followed by a wash in alkaline buffer to “blue” the counterstain.
The slides were then dehydrated and mounted using automated
procedures (Leica Microsystems).
Figure 1. Pattern of expression of proteases and VEGFA in omental metastases of serous ovarian carcinoma. Four-micrometer sections
were stained for the expression of MMP9 (A, B), MMP2 (C, D), CD (E, F), CL (G, H), and VEGFA (I, J) using the Bond Polymer Refine
Detection System. Nuclei are stained blue, whereas brown staining indicates the presence of the assessed protein. Scale bars, 100 μm
(A, C, E, G, I) and 50 μm (B, D, F, H, J). Representative images are shown.
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Immunoreactivity was evaluated over each whole slide in a
semiquantitative way by three researchers blinded to the category
of each section. Scoring criteria were determined during a
preliminary evaluation using a multiheaded microscope to reach
a consensus. The immunohistologic expression of each protein was
scored for intensity of staining and percentage of positive cells over
the whole slide, in three cell types: cancer, endothelial, and
mesothelial cells, producing a total score (TS). The following
scoring system was applied: intensity of staining scored (1) none or
weak, (2) moderate, and (3) strong, and percentage of positive
cells was scored (0) 0% to 5%, (1) 6% to 25%, (2) 26% to 75%,
and (3) 76% to 100%. TS was calculated (for each protein in each
cell type) as the mean sum (from the three researchers) of the
intensity and percentage scores, i.e., between 1 and 6 with a score
of 6 indicating strongest staining in the majority of cells. Theinterobserver variation was checked using weighted Kappa statistic
for comparing three observers as described previously [16].
Clinicopathologic Data
Benign cysts (serous cystadenomas) were surgically removed,
whereas the metastatic serous EOC patients' initial treatment was
by surgical debulking. Adjuvant chemotherapy in the malignant group
was a standard platinum-based regime directed by a gynecological
oncologist. None of the subjects selected for the study had
endometriosis or had received recent chemotherapy before surgery
(within 10 months). FIGO staging, distant metastasis status, and
ascites volume were defined by the operating gynecological surgeons.
DSS was defined as survival without death due to ovarian cancer, and
OSwas defined as survival without death due to any cause. Relapse was
defined as symptomatic disease based on physical examination,
imaging studies, and CA125 levels, or for patients initially diagnosed
Figure 2.Median overall expression levels, i.e., TSs and individual patient expression levels of MMP9, CL, CD, and VEGFA in cancer cells,
endothelial cells (endo), andmesothelial cells (meso). A heat map of expression of each protein in all cell types studied in each patient was
generated using R Statistical Computing software (v3.0.1). Protein TSs were calculated on the basis of the sum of staining intensity and
percentage of positive cells. The median of the TS for all patients in each group is presented. For presentation, the expression of the
proteins is clustered into two distinct modes: moderate-to-high (TSs ranging 2-5) and weak-to-moderate expression (TSs ranging 1-2.333).
Differential expression of median TS for each protein in the mesothelium and endothelium in the two patient groups was assessed by
Wilcoxon signed-rank test, and P b .01 was considered as significant, n = 19 or 20 (see Table 1) for omental endothelial and mesothelial
tissues.
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disease. On the basis of DSS, patients were divided into two relapse
groups: recurrent disease (present) and no recurrent disease (absent).
On the basis of CA125 level, patients were grouped as low (b35 IU/ml)
and high (≥35 IU/ml).
Statistical Analysis
For statistical analysis, medians of TS means were used. In all the
subsequent analyses, the R Statistical Language [17] was used. All
correlation coefficients presented in this manuscript are “rho”
coefficients from Spearman rank test. Survival analyses, survival plots,
and Cox proportional hazards regression models were generated by the
package “survival” [18,19]. The P values presented in the plots are
derived from the log-rank test. The survival function of DSS and OS
was estimated using the Kaplan-Meier method. To determine the effect
on likelihood of survival of combinations of proteins/clinicopathologic
variables, the tree-structured survival analysis was used [20].Results
Clinical Demographics and Pattern of Protein Expression
Patient clinical and pathologic data are summarized in Table 1. The
follow-up for both groups was 60 months. Benign and metastatic
ovarian tumors were both of serous type to exclude potential variations
in protein expression between tumor subtypes. The interobserver
variation was 0.8 (for all assessed proteins in all cell types).Cancer Protein Expression. The expression patterns of all proteins
were initially characterized in EOC cells. Representative EOC
staining patterns for each protein are illustrated and discussed in
Figure 1. Relatively high expression (median TS N 3.5) was observed
for all proteins except MMP2 (Figure 2). The TS for MMP2 was 1
indicating minimal expression (data not shown), and thus, this
protein was not included for further analysis. EOC cell TS of
expression of each expressed protein in all individual patients studied
and overall median TSs for each protein are shown in Figure 2.
Endothelium and Mesothelium Protein Expression. Next, we assessed
expression of protein targets in the endothelium and mesothelium of
both groups. Representative images, together with a description of the
staining patterns, are presented in Figure 3. Endothelial and
mesothelial cell TSs of expression of each protein in all individual
patients studied and overall median TSs for each protein are shown in
Figure 2. The malignant group mesothelium expressed the highest
levels of MMP9, VEGFA, and CL, while the endothelium was
particularly immunoreactive for VEGFA and CL. Mesothelial and
endothelial MMP2 immunoreactivity was mainly negative or weakly
positive in both groups. MMP9 immunoreactivity exhibited mainly
diffuse, cytoplasmic staining, with stronger perinuclear pattern of
staining observed in the mesothelium. This staining pattern suggests
storage and processing of MMP9 in vesicles in these cell types before
release at the cell surface. MMP9 expression was stronger in
mesothelial cells close to the metastatic tumor and in mesothelial
cells with a stratified, inflamed appearance than those remote from
Figure 3. Pattern of expression of proteases and VEGFA in endothelium and mesothelium of the control and malignant omentum. Four-
micrometer sections were stained for expression of MMP9 (A, B), MMP2 (C, D), CD (E, F), CL (G, H), and VEGFA (I, J) using the Bond
Polymer Refine Detection System. Description of pattern of staining is presented in the enclosed table. A, C, E, G, I—control omentum;
B, D, F, H, J—malignant omentum. Arrowheads indicate mesothelium, stars indicate blood vessels, and C indicates the presence of
metastatic lesion of EOC. Nuclei are stained blue, whereas brown staining indicates the presence of the assessed protein. Scale bar,
100 μm.
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pattern, supporting their reported intracellular localization in
lysosomal and secretory vesicles. CD expression was also stronger in
inflamed, stratified mesothelium and mesothelium close to metastatic
tumor. Lastly, VEGFA showed a diffuse, cytoplasmic localization(homogenous) in endothelium and mesothelium of both groups
studied. Swollen, darkly stained VEGFA-positive mesothelial cells
were often observed in the malignant group. Perivascular cells, e.g.,
vascular smooth muscle cells, exhibited various degrees of immuno-
reactivity for MMP9, CD, CL, and VEGFA in both groups.
Figure 4. Correlations in cell type–specific expression levels of MMP9, CD, CL, and VEGFA between (A) cell type and protein and
(B) patient clinicopathologic variables. (A) Intercell and intracell type correlations between protein expression in omentum from all
patients assessed by Spearman correlation, n = 39. (B) Spearman rank correlation test for protein expression and clinicopathologic
variables for all patients. Patients were categorized as described in theMaterials andMethods section and in Table 1, n=39. r=Spearman's
rank correlation coefficient (rho), P = Spearman rank correlation P value. P b .01 was considered as significant.
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Clinicopathologic Features
Previous work suggests that expression of proteases and VEGFA
increases as tissue changes from a normal-to-benign-to-malignant
phenotype, presumably associated with the induction of a “pro-
angiogenic” state [8,21]. Initial analysis indicated that omental
endothelial expression of MMP9, CL, and VEGFA and omental
mesothelial expression of CD, MMP9, and VEGFA were significantly
higher in the malignant group compared to the control group
(Figure 2). We then investigated intercell and intracell type
(endothelial and mesothelial) correlations in expression of all
investigated proteins, because a complex interplay between proteases
and VEGFA during tumor progression has been reported [9].
Numerous nominal significant associations were observed (complete
data in Table W2). However, most of the highly significant
associations (P b .001, r N 0.5) clustered with high mesothelial
MMP9 and VEGFA expression (Figure 4A), indicating the
development of a pro-metastatic phenotype in the mesothelium.
We next analyzed the relationship between clinicopathologic
parameters and protein expression in the omental endothelium and
mesothelium. Several significant correlations were evident (for r and
P values, see Figure 4B). High endothelial and mesothelial expression
of MMP9 correlated with an increase in all assessed clinicopathologic
variables, whereas high mesothelial and endothelial expression of
VEGFA associated with increased CA125 levels, as did high
mesothelial CD expression.The Impact of Omental VEGFA and Protease Expression on
Clinical Outcome
Kaplan-Meier survival curves were plotted followed by log-rank
tests for DSS and OS to determine the relationship between protein
expression levels in endothelium and mesothelium and survival. High
expression of MMP9 and VEGFA in endothelium and mesothelium
and high mesothelial expression of CD were positively associated with
EOC disease-specific death (DSS; P = .0012, P b .0001, P = .0084,
P = .021, P = .011, respectively; Figure 5, A–E). However,
significantly reduced OS was only observed in patients with high
MMP9 expression in endothelium and mesothelium (P = .0097 and
P = .032, respectively; Figure 5, F and G).
To explore the prognostic relevance of endothelial/mesothelial
changes in protein expression on DSS, a univariate analysis of protein
expression for clinical outcome was performed. Cox proportional
hazards regression modeling revealed that patients with high
expression of MMP9 in either the endothelium or mesothelium
had the greatest risk of shorter median DSS [hazard ratio (HR) =
6.16, 95% confidence interval (CI) = 1.76-21.6, P = .0045; HR =
11.42, 95% CI = 2.59-50.35, P = .0013, respectively; Table 2A].
Other significant risks of reduced DSS were high mesothelial
expression of CD and high mesothelial or endothelial expression of
VEGFA; however, these risks were less pronounced (Table 2A).
Among clinicopathologic variables, the presence of ascites was most
strongly correlated with reduced DSS (HR = 6.35, 95% CI = 2.01-
20.1, P = .002; Table 2B).
Figure 5. High expression of MMP9 in either endothelium or mesothelium associates with significantly reduced EOC DSS and OS.
Kaplan-Meier survival curves were plotted for (A–E) DSS and (F, G) OS. n = 39, P values were calculated using the log-rank test. For
analysis, protein expression was classified as either high or low based on the median expression value of each protein of all samples
included in this study. High endothelial expression of VEGFA and high mesothelial expression of CD also associated with reduced DSS
but not with OS.
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To define the protein expression pattern associated with the worst
clinical outcome, a tree-structured analysis for DSS and OS was
performed with patients stratified by MMP9 expression in either
mesothelium or endothelium, since MMP9 expression was the best
predictor of survival/death. Reduced DSS was observed in patients
with high endothelial or mesothelial MMP9 expression coupled with
high endothelial VEGFA expression (condition 1), high mesothelial
VEGFA expression (condition 2), and high mesothelial CD
expression (condition 3; DSS for MMP9, endothelium: P b .001
for all three associations; DSS for MMP9, mesothelium: P b .001 for
all three associations; see Figure 6, A–C, for endothelium and FigureW2, A–C, for mesothelium). However, only patients with high
endothelial MMP9 expression had significantly reduced OS (P =
.049, P = .038, and P = .034, respectively, for conditions 1, 2, and 3;
Figure 6, D and E). Follow-up tree-structured HR analysis indicated
that high endothelial MMP9 expression was the single best predictor
of reduced DSS and OS (DSS, HR = 6.16, 95% CI = 1.76-21.6, P =
.005; OS, HR = 4.59, 95% CI = 1.29-16.3, P = .019; for survival
trees, see Figure W2, D–F). An additive effect of decreased OS was
observed in patients with high expression of MMP9 in both
endothelium and mesothelium; however, the HR for DSS was not
further reduced compared to univariate analysis forMMP9 (OS, HR =
18.75, 95% CI = 2.43-144.75, P = .005; DSS, HR = 5.94, 95% CI =
Table 2. Association of Pro-Metastatic Protein Expression Pattern and Clinicopathologic
Characteristics with Length of Ovarian Cancer DSS.
A
Variable Expression Median DSS (Years) HR (95% CI) P
MMP9
Endothelium High 1.83 6.16 (1.76-21.61) .0045
Low 4.36
Mesothelium High 1.99 11.42 (2.59-50.35) .0013
Low 4.36
CD
Endothelium High 3.68 1.22 (0.35-4.25) .75
Low 4.36
Mesothelium High 2.41 3.25 (1.23-8.60) .018
Low 4.36
CL
Endothelium High 3.17 2.69 (0.94-7.66) .064
Low 4.36
Mesothelium High 3.71 1.83 (0.70-4.83) .22
Low 4.36
VEGFA
Endothelium High 2.88 3.70 (1.30-10.54) .014
Low 4.36
Mesothelium High 3 3.19 (1.12-9.1) .03
Low 4.36
B
Variable Expression Median DSS (Years) HR (95% CI) P
CA125 High 2.42 4.61 (1.04-20.5) .045
Low 4.36
Ascites Present 1.42 6.35 (2.01-20.1) .002
Absent 4.36
Distant metastasis Present 1.21 3.33 (1.20-9.23) .02
Absent 4.36
(A) Association of omental endothelial and mesothelial expression levels of MMP9, CL, CD, and
VEGFA with DSS. Cox proportional hazard regressions of endothelial and mesothelial expression
(medians) of each protein in all patients were calculated to test association with DSS. P b .05 was
considered as significant. Patients were categorized on the basis of median protein TS for each
protein in each cell type. Elevated MMP9 expression in omental endothelium and mesothelium was
associated with the shortest length of DSS (HR = 6.16, 95% CI = 1.76-21.6, P = .0045; HR =
11.42, 95% CI = 2.59-50.35, P = .0013, respectively).
(B) Association of CA125 levels, presence of ascites, and presence of distant metastases with DSS. Cox
proportional hazard regressions of CA125 levels, ascites, and distant metastasis of all patients were calculated
to test association with DSS. P b .05 was considered as significant. Patients were categorized as described in
the Materials and Methods section and in Table 1. The presence of ascites had highest impact on reduced
DSS (HR = 6.35, 95% CI = 2.01-20.1, P = .002).
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the predictive significance of elevated endothelial MMP9 expression,
we generated a tree-structured analysis of multivariable Cox
proportional hazard regression models for DSS and OS where,
initially, all clinicopathologic parameters were included. In our final
model, both elevated endothelial MMP9 expression (DSS, HR = 6.16,
95% CI = 1.76-21.6, P = .005; OS, HR = 4.59, 95% CI = 1.29-16.3,
P = .019) and the presence of ascites (DSS, HR = 9.92, 95%CI = 2.15-
45.7, P = .003; OS, HR = 43.2, 95% CI = 5.33-350, P = .0004) were
independent predictors of DSS and OS, together resulting in worst
patient prognosis (Figure 6G).
Discussion
This study demonstrates an increase in expression of pro-angiogenic
proteases and VEGFA in omental tissue with metastasized EOC
compared to control omentum. Specifically, we show for the first time
that omentum with metastatic disease has significantly increased
endothelial expression of MMP9, CL, and VEGFA and mesothelial
expression of CD, MMP9, and VEGFA. Further analysis indicated
that high omental mesothelial and endothelial expression of MMP9and VEGF and high mesothelial expression of CD is associated with
decreased DSS and/or OS in EOC. Most importantly, high omental
endothelial MMP9 expression together with the presence of ascites
predicts poor prognosis.
MMPs and cathepsins have been implicated in tumor progression
and have been widely investigated in cancers showing overexpression
of these proteases, including ovarian cancer [22–25]. Similarly,
altered expression of pro-angiogenic factors such as VEGFA has been
investigated in ovarian cancer, since angiogenesis is known to
correlate with prognosis [10,26]. Importantly, ovarian cancer–
secreted CD, CL, and MMP9 have been shown to regulate a range
of cellular responses of omental microvascular endothelial cells in
in vitro studies, highlighting their role as key alternative angiogenic
mediators during omental progression of EOC [27]. Our data
support these previous studies since the metastasized EOC cells were
strongly immunoreactive for MMP9 and VEGFA and moderately for
CD and CL. However, little or no expression of MMP2 was observed,
in contrast to a previous study by Schmalfeldt et al. [28].
In addition to the expected expression of pro-angiogenic factors in
the metastasized EOC, our study is the first to specifically show
overexpression of MMPs, cathepsins, and VEGFA in the endothe-
lium and mesothelium of the omental tissue surrounding EOC
metastases. These factors are likely to have a close pro-angiogenic
relationship since protease degradation/remodeling of the ECM
during angiogenesis can release pools of ECM-bound growth factors
(i.e., VEGFA and basic fibroblast growth factor) that facilitate new
vessel growth [7,29]. Importantly, our data suggest that the
dissemination of EOC may engage a “cellular triangle” involving
cancer cells (primary invaders and switchers of the microenviron-
ment), endothelial cells (mediators of tumor-induced angiogenesis),
and mesothelial cells (signal disseminators). Thus, invasion of the
omentum by EOC is associated with pro-angiogenic protein
expression in the surrounding omental tissue creating a microenvi-
ronment conducive to metastatic growth and disease progression. It is
not possible to conclude from our data whether this is driven by the
cancer cells, the endothelial/mesothelial cells, or a feedback loop
between all three cell types “feeding” metastasis growth. However,
our observation that both MMP9 and CD expression was stronger in
mesothelial cells close to the metastatic tumor suggests that a
paracrine effect of factors secreted from the tumor cells contributes to
the increased MMP9 and CD expression. For MMP9, this is
supported by the observation that the secretome of colorectal tumor
cells induced increased expression of MMP9 in primary human
omental mesothelial cells [30]. In contrast, Davidson and co-workers
[31] showed that while MMP2/9 protein expression was detected in
primary and omental metastases of EOC, higher expression was
found in pleural and peritoneal effusions containing active
mesothelial cells and concluded that the MMPs were predominantly
synthesized by EOC cells in effusions, where cells acquired their
metastatic potential from the local microenvironment, and by local
native cells, i.e., mesothelial cells.
Importantly, high mesothelial and endothelial expression of
MMP9 and VEGF, high mesothelial expression of CD, and the
presence of ascites were associated with significantly reduced DSS in
our study. Previously, Kamat and colleagues found that stromal
expression of MMPs (particularly MMP9 and MT1-MMP in
fibroblasts and endothelial cells) was an independent predictor of
shorter DSS in patients with EOC [13]. In our investigation, both
endothelium and mesothelium appeared to be involved in defining a
Figure 6. Elevated MMP9 expression in endothelial cells independently predicts reduced EOC DSS and OS and, coupled with the
presence of malignant ascites, predicts worst patient outcome. Kaplan-Meier survival curves are shown for each “node” of the tree-
structured analysis: (A–C) DSS and (D–F) OS; condition 1—high endothelial MMP9 expression coupled with high endothelial VEGFA
expression, condition 2—high endothelial MMP9 expression coupled with high mesothelial VEGFA expression, condition 3—high
endothelial MMP9 expression coupled with high mesothelial CD expression; n = 39; P values were calculated using the log-rank test.
(G) Multivariable Cox proportional regression tree-structured analysis of endothelial MMP9 expression and clinicopathologic parameter
(ascites), n = 39. For analysis, expression of each protein was characterized as high or low based on the median expression value of all
samples included in this study.
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expression of not only proteases (i.e., MMP9 and CD) but also
VEGFA.
Interestingly, only patients with high endothelial expression of
MMP9 coupled with high mesothelial VEGFA or CD or endothelial
VEGFA expression had significantly reduced OS. This complements
previous in vitro data indicating an upstream regulatory function of
CD onMMP9 activity that translates to an enhanced endothelial pro-
angiogenic potential [32]. Interestingly, CD has been postulated as amitogenic factor acting on both cancer and endothelial cells
independently of its catalytic activity, affecting cell proliferation,
angiogenesis, and apoptosis [33]. We postulate that high cancer and
mesothelial CD expression might contribute to EOC growth and
facilitate a pro-angiogenic omental environment. However, confir-
mation would require further study.
In conclusion, we have shown increased expression of pro-
angiogenic proteases and VEGF in the endothelium and mesothelium
in omentum hosting metastatic EOC and that high endothelial
276 Protease Expression and Ovarian Cancer Prognosis Winiarski et al. Translational Oncology Vol. 7, No. 2, 2014expression of MMP9 together with a presence of malignant ascites
predicts poor clinical outcome. We suggest that there is a complex
cross-talk between cancer, mesothelial, and endothelial compartments
in the omentum with metastases contributing to disease progression
and that targeting pro-angiogenic proteases and VEGF in both
omental mesothelium and endothelium may be required for
optimum treatment of EOC-induced angiogenesis and disease
progression.
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EOC (cancer) and Control Cystadenoma, and Antigen Recovery Determination (no PT, no pretreatm
(EDTA, high pH) for 10 or 20 minutes at 100°C).
Antibody Dilution and Pretreatment
MMP2 (clone 17B11) 1:50 HIER ER2 20′
1:100 HIER ER2 20′
1:200 HIER ER2 20′
MMP9 (clone 15W2) 1:50 No PT
1:100 No PT
1:200 No PT
CD (clone C5) 1:50 No PT
1:100 No PT
1:200 No PT
CL (clone 33/2) 1:3000 HIER ER2 10′
1:5000 HIER ER2 20′
1:10000 HIER ER2 20′
VEGFA (clone VG-l) 1:200 HIER ER2 20′
1:400 HIER ER2 20′
1:800 HIER ER2 20′
1:200 HIER ER2 20′
1:400 HIER ER2 20′
1:800 HIER ER2 20′iminary Dilutions Tested on Positive Controls and on Omental Samples Taken from Patients with
ent; HIER ER2 10′/20′, heat-induced epitope retrieval using Bond Epitope Retrieval Solution 2
Control Tissues Omental Samples
Inflamed large bowel Cancer/cystadenoma
Inflamed large bowel
Inflamed large bowel
Liver Cancer/cystadenoma
Liver
Liver
Liver
Liver Cancer/cystadenoma
Liver
Liver
Liver Cancer/cystadenoma
Liver
Ovary (corpus luteum) Cancer/cystadenoma
Ovary (corpus luteum)
Ovary (corpus luteum)
Angiosarcoma
Angiosarcoma
Angiosarcoma
FigureW1. Positive control tissue staining. Four-micrometer sections were stained for expression of MMP9 (A), MMP2 (B), CD (C), CL (D),
and VEGF (E) using the Bond Polymer Refine Detection System. Expression of antibodies was determined in the liver (A, C, and D),
inflamed large bowel (B), and corpus luteum of the ovary. b, inflamed submucosal cells of the large bowel; , corpus luteum. Scale bar,
100 μm.
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Table W2. All investigated intercell and intracell type correlations between protein expression in the omentum of all patients studied assessed by Spearman rank correlation test, n = 39; r = Spearman rank
correlation coefficient (rho), P = Spearman rank correlation P value; P b .01 was considered as significant.
Variable Spearman Rank Correlation Coefficients (r)
MMP9 Endothelium MMP9 Mesothelium MMP2 Mesothelium CD Endothelium CD Mesothelium CL Endothelium CL Mesothelium VEGFA Endothelium
MMP9 endothelium 1.000 – – – – – – –
MMP9 mesothelium 0.551 1.000 – – – – – –
MMP2 mesothelium 0.160 0.195 1.000 – – – – –
CD endothelium 0.158 −0.258 −0.069 1.000 – – – –
CD mesothelium 0.381 0.710 0.197 0.031 1.000 – – –
CL endothelium 0.077 0.338 −0.029 0.040 0.163 1.000 – –
CL mesothelium 0.265 0.601 −0.029 −0.227 0.398 0.479 1.000 –
VEGFA endothelium 0.152 0.418 −0.022 −0.231 0.112 0.501 0.284 1.000
VEGFA mesothelium 0.338 0.653 0.066 0.029 0.516 0.480 0.542 0.569
Variable P Values
MMP9
Endothelium
MMP9
Mesothelium
MMP2
Mesothelium
CD
Endothelium
CD
Mesothelium
CL
Endothelium
CL
Mesothelium
VEGFA
Endothelium
MMP9 endothelium 1.000 – – – – – – –
MMP9 mesothelium b .001 1.000 – – – – – –
MMP2 mesothelium .330 .233 1.000 – – – – –
CD endothelium .336 .112 .677 1.000 – – – –
CD mesothelium .017 b .001 .230 .851 1.000 – – –
CL endothelium .643 .036 .859 .810 .321 1.000 – –
CL mesothelium .102 b .001 .860 .164 .012 .002 1.000 –
VEGFA endothelium .355 .008 .894 .157 .497 .001 .080 1.000
VEGFA mesothelium .035 b .001 .692 .860 b .001 .002 b .001 b .001
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FigureW2. Kaplan-Meier survival curves of DSS for each “MMP9mesothelial node” of the tree-structured analysis (A–C), n= 39; P values
were calculated using the log-rank test. Tree-structured hazards ratio analysis of endothelial MMP9 expression with other proteins in
endothelium or mesothelium (D–F). Protein expression was characterized as either high or low based on the median expression value of
each protein in all samples included in this study.
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